Literature DB >> 6967414

Mouse alloantibodies capable of blocking cytotoxic T cell function. II. Further study on the relationship between the blocking antibodies and the products of the Lyt-2 locus.

N Shinohara, U Hämmerling, D H Sachs.   

Abstract

The specificity of mouse alloantibodies which blocked allogeneic killer cells has been confirmed as Ly-2.2 using B6 X C3H recombinant inbred (RI) strains. All of the RI strains tested were sensitive to the cell-mediated lymphocytotoxicity (CML)-blocking effect of our C3H anti-B 10.BR antisera and also carried the Lyt-2b allele. This result and studies using Lyt-2-congenic strains firmly localized the genes encoding the target antigen of CML-blocking antibodies in or near the Lyt-2 locus. In addition, a monoclonal anti-Lyt-2.2 antibody was found to block the CML reaction of B6 killer cells, but not that of B6 Ly-2.1 killers. Blocking antibodies to one allele blocked killing by Lyt-2-heterozygous F1 killer cells, but the inhibition curve reached a plateau at a significantly lower level than that seen on the killer cells of the sensitive parent. Our results thus suggest that Lyt-2 antigens are of functional significance on killer T cells, but do not reveal whether or not that significance involves the T cell receptor.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967414     DOI: 10.1002/eji.1830100804

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

Authors:  T W Chang; P C Kung; S P Gingras; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

2.  Significance of Lyt phenotypes: Lyt2 antibodies block activities of T cells that recognize class 1 major histocompatibility complex antigens regardless of their function.

Authors:  S L Swain
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

3.  A role of L3T4+ antigen in the Con A response of regenerating splenic L3T4+ T cells after Cy treatment.

Authors:  Z Ikezawa; M Sato; I Aoki
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

4.  Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing.

Authors:  D Davignon; E Martz; T Reynolds; K Kürzinger; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

5.  A low polymorphic mouse H-2 class I gene from the Tla complex is expressed in a broad variety of cell types.

Authors:  C Transy; S R Nash; B David-Watine; M Cochet; S W Hunt; L E Hood; P Kourilsky
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

6.  Possible involvement of the T4 molecule in T cell recognition of class II HLA antigens. Evidence from studies of CTL-target cell binding.

Authors:  W E Biddison; P E Rao; M A Talle; G Goldstein; S Shaw
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

7.  The major histocompatibility complex-restricted antigen receptor on T cells. II. Role of the L3T4 product.

Authors:  P Marrack; R Endres; R Shimonkevitz; A Zlotnik; D Dialynas; F Fitch; J Kappler
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

8.  The role of L3T4 in recognition of Ia by a cytotoxic, H-2Dd-specific T cell hybridoma.

Authors:  J L Greenstein; J Kappler; P Marrack; S J Burakoff
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

9.  Possible involvement of the OKT4 molecule in T cell recognition of class II HLA antigens. Evidence from studies of cytotoxic T lymphocytes specific for SB antigens.

Authors:  W E Biddison; P E Rao; M A Talle; G Goldstein; S Shaw
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

10.  Role of L3T4 in antigen-driven activation of a class I-specific T cell hybridoma.

Authors:  J L Greenstein; B Malissen; S J Burakoff
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.